Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
Abroad (travel likely)RecruitingPHASE2
Conditions
Kaposi Sarcoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Contact: Study coordinator (National Cancer Institute Referral Office) · ncimo_referrals@mail.nih.gov · 888-624-1937
Study leads
Ramya M Ramaswami, M.D.
Principal Investigator
National Cancer Institute (NCI)